{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:34:31Z","timestamp":1764599671259,"version":"3.46.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.acuroe.2025.501864","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:34:03Z","timestamp":1760222043000},"page":"501864","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cisplatin-induced AKI risk stratification and safety of dose reduction in urothelial carcinoma patients with renal impairment"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3581-5122","authenticated-orcid":false,"given":"S.","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Higa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Bamba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Kanaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuroe.2025.501864_bib0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clgc.2011.10.004","article-title":"Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer","volume":"10","author":"Tsao","year":"2012","journal-title":"Clin Genitourin Cancer."},{"key":"10.1016\/j.acuroe.2025.501864_bib0010","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cncr.22031","article-title":"Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder","volume":"107","author":"Dash","year":"2006","journal-title":"Cancer."},{"key":"10.1016\/j.acuroe.2025.501864_bib0015","article-title":"Incidence and risk factors of acute kidney injury in patients with malignant tumors: a systematic review and meta-analysis","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Cancer."},{"key":"10.1016\/j.acuroe.2025.501864_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1173578","article-title":"Acute kidney injury and acute kidney disease in high-dose cisplatin-treated head and neck cancer","volume":"13","author":"Trevisani","year":"2023","journal-title":"Front Oncol."},{"key":"10.1016\/j.acuroe.2025.501864_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2023.106579","article-title":"Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience","author":"Cavalieri","year":"2023","journal-title":"Oral Oncol."},{"key":"10.1016\/j.acuroe.2025.501864_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142225","article-title":"Understanding the risk factors and long-term consequences of cisplatin-associated acute kidney injury: an observational cohort study","volume":"10","author":"Bhat","year":"2015","journal-title":"PLoS One."},{"key":"10.1016\/j.acuroe.2025.501864_bib0035","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/COC.0000000000000301","article-title":"Retrospective analysis of cisplatin nephrotoxicity in patients with head and neck cancer receiving outpatient treatment with concurrent high-dose cisplatin and radiotherapy","volume":"41","author":"Faig","year":"2018","journal-title":"Am J Clin Oncol."},{"key":"10.1016\/j.acuroe.2025.501864_bib0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25021074","article-title":"The value of urinary NGAL, KIM-1, and IL-18 measurements in the early detection of kidney injury in oncologic patients treated with cisplatin-based chemotherapy","volume":"25","author":"Szumilas","year":"2024","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.acuroe.2025.501864_bib0045","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-077169","article-title":"Derivation and external validation of a simple risk score for predicting severe acute kidney injury after intravenous cisplatin: cohort study","volume":"384","author":"Gupta","year":"2024","journal-title":"BMJ."},{"key":"10.1016\/j.acuroe.2025.501864_bib0050","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1200\/JCO.2017.75.7161","article-title":"Development and validation of a risk prediction model for acute kidney injury after the first course of cisplatin","volume":"36","author":"Motwani","year":"2018","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuroe.2025.501864_bib0055","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/sj.bjc.6600884","article-title":"Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients","volume":"88","author":"de Jongh","year":"2003","journal-title":"Br J Cancer."},{"key":"10.1016\/j.acuroe.2025.501864_bib0060","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10157-023-02415-0","article-title":"Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022","volume":"28","author":"Yanagita","year":"2024","journal-title":"Clin Exp Nephrol."},{"issue":"10","key":"10.1016\/j.acuroe.2025.501864_bib0065","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acuroe.2025.501864_bib0070","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s002800050661","article-title":"Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods","volume":"40","author":"Stewart","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.acuroe.2025.501864_bib0075","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s13063-015-0772-4","article-title":"Effects of a DPP4 inhibitor on cisplatin-induced acute kidney injury: study protocol for a randomized controlled trial","volume":"16","author":"Baek","year":"2015","journal-title":"Trials."},{"issue":"6","key":"10.1016\/j.acuroe.2025.501864_bib0080","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1001\/jamaoncol.2025.0756","article-title":"Intravenous magnesium and cisplatin-associated acute kidney injury","volume":"11","author":"Gupta","year":"2025","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.acuroe.2025.501864_bib0085","article-title":"Reassessing cisplatin eligibility in urothelial carcinoma: a retrospective study on dose reduction strategies","volume":"17","author":"Yamamoto","year":"2024","journal-title":"Cureus."},{"key":"10.1016\/j.acuroe.2025.501864_bib0090","article-title":"Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer","volume":"5","author":"Galsky","year":"2024","journal-title":"Cell Rep Med."},{"key":"10.1016\/j.acuroe.2025.501864_bib0095","doi-asserted-by":"crossref","first-page":"167","DOI":"10.21873\/invivo.11454","article-title":"Gemcitabine plus cisplatin split versus gemcitabine plus carboplatin for advanced urothelial cancer with cisplatin-unfit renal function","volume":"33","author":"Izumi","year":"2019","journal-title":"In Vivo."},{"key":"10.1016\/j.acuroe.2025.501864_bib0100","article-title":"Split-dose cisplatin in patients with locally advanced or metastatic urothelial carcinoma: a systematic literature review and network meta-analysis","volume":"22","author":"O\u2019Dwyer","year":"2024","journal-title":"Clin Genitourin Cancer."},{"issue":"19","key":"10.1016\/j.acuroe.2025.501864_bib0105","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578625001891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578625001891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:30:53Z","timestamp":1764599453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173578625001891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2173578625001891"],"URL":"https:\/\/doi.org\/10.1016\/j.acuroe.2025.501864","relation":{},"ISSN":["2173-5786"],"issn-type":[{"type":"print","value":"2173-5786"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cisplatin-induced AKI risk stratification and safety of dose reduction in urothelial carcinoma patients with renal impairment","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuroe.2025.501864","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2025.501864","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"501864"}}